Scientists at the QIMR Berghofer Medical Research Institute have achieved a groundbreaking advancement in creating the first-ever vaccine against the Epstein-Barr virus (EBV), responsible for infectious mononucleosis and linked to cancer and multiple sclerosis. The vaccine stimulates antibodies and T cells, integral components of the immune system, to combat EBV. It also offers a unique defense against EBV-associated tumors, potentially preventing secondary conditions like brain inflammation and multiple sclerosis. The team aims to begin human clinical trials, expected to start around 2024 or 2025, with initial funding secured from industry partners. This milestone holds promise for addressing EBV-related health concerns.
Related Posts
Low volcanic emissions caused ‘Snowball Earth’ 700m years ago.
The giant snowball Earth event 700 million years ago was triggered by all-time low volcanic carbon emissions, leading to a 57-million-year-long global ice age. Scientists now believe that the reduction in volcanic activity resulted in decreased levels of carbon dioxide in the atmosphere, leading to a significant cooling effect. This prolonged glaciation period, known as […]
LIGO’s Enhanced Sensitivity Reveals New Cosmic Insights
LIGO, the Laser Interferometer Gravitational-Wave Observatory, has achieved a remarkable advancement in sensitivity by employing a technique known as frequency-dependent squeezing. This innovative approach enables LIGO to transcend the quantum limitations that previously hindered its measurements. A substantial 60% increase in the detection rate of cataclysmic events, like the collision of black holes and […]
How to Use Idioms in Research Articles?
What Is an Idiom? An idiom is a phrase that has been in use for a long time and has come to take on a unique and distinct meaning, often different from the literal meaning of its individual components. Idioms are common in everyday language and are typically used to express a sentiment or emotion. […]